Selective Bibliography of Dr. Jason D. Marshall
Vaccine, Immunity, and Cancer Directorate

"Optimization of a novel HPV vaccine with next generation adjuvant formulations"
Tuesday, August 17, 2021


  1. Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, Song Y, Elsaadi A, Deng N, Vilar E, Fuchs V, Nelius N, Yuan, Ahadova A, Sei S, Shoemaker RH, Umar A, Wei L, Liu S, Bork P, Edelmann W, von Knebel Doeberitz M, Lipkin SM, Kloor M
    Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model
    Gastroenterology [Epub ahead of print] : Jul 2 2021

  2. Marin A, Chowdhury A, Valencia SM, Zacharia A, Kirnbauer R, Roden RBS, Pinto LA, Shoemaker RH, Marshall JD, Andrianov AK
    Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine
    Nanomedicine: Nanotechnology, Biology, and Medicine 33: 102359 Apr 2021

  3. Valencia SM, Zacharia A, Marin A, Matthews RL, Wu CK, Myers B, Sanders C, Difilippantonio S, Kirnbauer R, Roden RB, Pinto LA, Shoemaker RH, Andrianov AK, Marshall JD
    Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP
    Human Vaccines & Immunotherapeutics [Epub ahead of print] :1-14 Feb 11 2021

  4. Zacharia A, Harberts E, Valencia SM, Myers B, Sanders C, Jain A, Larson NR, Middaugh CR, Picking WD, Difilippantonio S, Kirnbauer R, Roden RB, Pinto LA, Shoemaker RH, Ernst RK, Marshall JD
    Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists
    Vaccine 39 (2):292-302 Jan 8 2021

  5. Maynard SK, Marshall JD, MacGill RS, Yu L, Cann JA, Cheng LI, McCarthy MP, Cayatte C, Robbins SH
    Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication
    BMC Cancer 19 (1):540 Jun 6 2019

  6. Gregg KA, Harberts E, Gardner FM, Pelletier MR, Cayatte C, Yu L, McCarthy MP, Marshall JD, Ernst RK
    A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model
    Vaccine 36 (28):4023-4031 Jun 27 2018

  7. Lin R, Heeke D, Liu H, Rao E, Marshall JD, Chio V, Cataniag F, Yu L, Zuo F, McCarthy MP
    Development of a robust, higher throughput green fluorescent protein (GFP)-based Epstein-Barr Virus (EBV) micro-neutralization assay
    Journal of Virological Methods 247: 15-21 Sep 2017

  8. Cayatte C, Marin A, Rajani GM, Schneider-Ohrum K, Snell Bennett A, Marshall JD, Andrianov AK
    PCPP-Adjuvanted Respiratory Syncytial Virus (RSV) sF Subunit Vaccine: Self-Assembled Supramolecular Complexes Enable Enhanced Immunogenicity and Protection
    Molecular Pharmaceutics 14 (7):2285-2293 Jul 3 2017

  9. Iyer V, Cayatte C, Marshall JD, Sun J, Schneider-Ohrum K, Maynard SK, Rajani GM, Bennett AS, Remmele RL, Jr., Bishop SM, McCarthy MP, Muralidhara BK
    Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products
    Journal of Pharmaceutical Sciences 106 (6):1490-1498 Jun 2017

  10. Gregg KA, Harberts E, Gardner FM, Pelletier MR, Cayatte C, Yu L, McCarthy MP, Marshall JD, Ernst RK
    Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
    mBio 8 (3):May 9 2017







Date Last Updated: 7/13/2021